Alimera up 70% on success at last for Iluvien
This article was originally published in Scrip
Alimera's treatment for diabetic macular oedema Iluvien (fluocinolone acetonide) is set to reach its first markets in the EU, giving a 70% share price boost to the company that has endured repeated rejections for the product in the US. Shares in the company reached a day high of $4.25 and closed at $3.94 on 28 February.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.